Claims for Patent: 5,294,636

Summary for Patent: 5,294,636

Title:	Crystalline form of indole derivative and pharmaceutical method thereof
Abstract:	A physical form of N-(4-(5 -(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl)-3-methoxybenzoyl)-2-methylbenzenesulphonamide substantially free of other physical forms, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks occuring at 2(theta)=8.1, 13.7, 16.4, 20.5 and 23.7 degrees and an infra-red spectrum (0.5% in KBr) having sharp peaks at 3370, 1670, 1525, 1490, 1280, 890, 870 and 550 cm-1, a process for its preparation and pharmaceutical compositions containing it. Also disclosed is a flowable preparation of the physical form which is in the form of soft pellets, and a process for obtaining this preparation.
Inventor(s):	Martin P. Edwards, John D. Sherwood
Assignee:	AstraZeneca UK Ltd , Syngenta Ltd
Application Number:	US07/805,426
Patent Claims:	1. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks occuring at 2θ=8.1°, 13.7°, 16.4°, 20.5° and 23.7°; an infra-red spectrum (0.5% in KBr) having sharp peaks at 3370, 1670, 1525, 1490, 1280, 890, 870 and 550 cm- ; and a melting point in the range of 190° to 200° C. 2. A pharmaceutical composition, which comprises an effective amount of a physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide as claimed in claim 1 and a pharmaceutically acceptable carrier. 3. A pharmaceutical composition as claimed in claim 2, which composition is suitable for administration by a metered dose inhaler, and comprises a pharmaceutically acceptable propellant. 4. A composition as claimed in claim 3, in which the propellant comprises trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane or 1,1,1,2-tetrafluoroethane. 5. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide substantially free of other physical forms, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks occuring at 2θ=8.1°, 13.7°, 16.4°, 20.5 ° and 23.7°; an infra-red spectrum (0.5% in KBr) having sharp peaks at 3370, 1670, 1525, 1490, 1280, 890, 870 and 550 cm-1 ; and a melting point in the range of 190° to 200° C. and which is in the form of soft pellets consisting of an agglomeration of particles, at least 90% of which have a diameter of less than 10 microns, which pellets have a diameter in the range of from 50 to 900 microns. 6. A method for antagonising one or more of the actions of leukotrienes in a living mammal, which comprises administering to said mammal an effective amount of a physical form of N-[4-[5-cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzene sulphonamide as claimed in claim 1.